Methyl-β-cyclodextrin suppresses the monocyte-endothelial adhesion triggered by lipopolysaccharide (LPS) or oxidized low-density lipoprotein (oxLDL)
Context Recent studies demonstrated the anti-atherosclerotic efficacy of cyclodextrin. However, it remains unclear whether cyclodextrin exerts the anti-atherosclerotic effect via regulating monocyte-endothelial adhesion. Objective To answer that question by recruiting methyl-β-cyclodextrin (MβCD) as...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_af14c7c844a7409d9fcce8b95d73097f | ||
042 | |a dc | ||
100 | 1 | 0 | |a Guo Chen |e author |
700 | 1 | 0 | |a Yun Zhou |e author |
700 | 1 | 0 | |a Wendiao Zhang |e author |
700 | 1 | 0 | |a Ying Qin |e author |
700 | 1 | 0 | |a Bo Wei |e author |
700 | 1 | 0 | |a Yanan Sun |e author |
700 | 1 | 0 | |a Yong Chen |e author |
245 | 0 | 0 | |a Methyl-β-cyclodextrin suppresses the monocyte-endothelial adhesion triggered by lipopolysaccharide (LPS) or oxidized low-density lipoprotein (oxLDL) |
260 | |b Taylor & Francis Group, |c 2021-01-01T00:00:00Z. | ||
500 | |a 1388-0209 | ||
500 | |a 1744-5116 | ||
500 | |a 10.1080/13880209.2021.1953540 | ||
520 | |a Context Recent studies demonstrated the anti-atherosclerotic efficacy of cyclodextrin. However, it remains unclear whether cyclodextrin exerts the anti-atherosclerotic effect via regulating monocyte-endothelial adhesion. Objective To answer that question by recruiting methyl-β-cyclodextrin (MβCD) as a cyclodextrin representative. Materials and methods Human umbilical vein endothelial cells (HUVECs) were not treated, or treated with 1 µg/mL liposaccharide (LPS) or 50 µg/mL oxidized low-density lipoprotein (oxLDL) for 12 h, 5 mM MβCD for 1 h, and LPS/oxLDL (1 and 50 µg/mL, respectively for 12 h) plus MβCD (5 mM for 1 h), respectively. The effects of MβCD on LPS/oxLDL-triggered monocyte-endothelial adhesion and related molecules in signalling pathways were evaluated via confocal microscopy, flow cytometry, RT-PCR, western blotting, and cell adhesion assay. Results MβCD with an IC50 of 27.66 mM (1 h treatment) exerted no significant cytotoxicity at ≤5 mM for ≤2 h. Compared with the control, both LPS and oxLDL induced an ∼2-3-fold increase in adhesion molecule expression (ICAM-1 and VCAM-1 at protein and mRNA levels) and NF-κB phosphorylation (p-NF-κB/pP65), an increase in IκB kinase (IKK), and a decrease in phosphorylated protein kinase B (p-Akt), respectively. Moreover, more monocytes (2-fold higher for LPS and 15% higher for oxLDL) were attached on LPS/oxLDL-stimulated HUVECs. 5 mM MβCD reversed the LPS/oxLDL-induced changes back to the control levels. Conclusions MβCD significantly suppresses the LPS/oxLDL-triggered monocyte-endothelial adhesion by downregulating adhesion molecule expression probably via LPS-IKK-NF-κB or oxLDL-Akt-NF-κB pathway. This study demonstrates a potential mechanism of the anti-atherosclerotic efficacy of cyclodextrin from the angle of monocyte-endothelial adhesion. | ||
546 | |a EN | ||
690 | |a cyclodextrins (cds) | ||
690 | |a human umbilical vein endothelial cells (huvecs) | ||
690 | |a thp-1 | ||
690 | |a atherosclerosis | ||
690 | |a tumour | ||
690 | |a nf-κb | ||
690 | |a cell adhesion | ||
690 | |a lipid raft | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutical Biology, Vol 59, Iss 1, Pp 1036-1044 (2021) | |
787 | 0 | |n http://dx.doi.org/10.1080/13880209.2021.1953540 | |
787 | 0 | |n https://doaj.org/toc/1388-0209 | |
787 | 0 | |n https://doaj.org/toc/1744-5116 | |
856 | 4 | 1 | |u https://doaj.org/article/af14c7c844a7409d9fcce8b95d73097f |z Connect to this object online. |